Estrella Immunopharma regains compliance with both Nasdaq listing requirements

Estrella Immunopharma, Inc.

Regained compliance with Stockholders' Equity Requirement after market value of listed securities exceeded $35M for 10 consecutive days ending Dec 10, 2024.
Regained compliance with Minimum Bid Price Requirement after closing bid price of common stock stayed at $1.00+ for 10 consecutive days ending Dec 10, 2024.
Both Nasdaq deficiency matters are now closed; no further action required.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.